logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Novartis: Psoriatic Arthritis Patients on Cosentyx Had No Radiologic Progression After 2 Years of Treatment

Good News about Novartis' Cosentyx ® for Psoriatic Arthritis Novartis ( NVS )   has good news for Cosentyx ® .  Data emerging out 0f the FUTURE 5 clinical trial on patients with psoriatic arthritis  (PsA)  showed that there was...

Read More

June 12, 2019

0

bluebird bio: Why This Firm's Stock Gained $6.37 Yesterday

Why has bluebird bio Been Hammered in the Market Recently? Investors should be asking why bluebird bio ( BLUE ) has been hammered in the market recently before asking why the stock gained $6.37 in trading yesterday. Why was it...

Read More

June 14, 2019

0

Pfizer to Acquire Array Biopharma at $48 a Share

Pfizer to Acquire Array Pfizer ( PFE ) announced that it has agreed to acquire Array Biopharma ( ARRY ) in a deal valued at $11.4 billion .  The Terms of the Agreement Under the terms of the agreement ,...

Read More

June 17, 2019

0

Novartis to Acquire The Medicines Company at $85 a Share

Novartis to Acquire The Medicines Company Novartis ( NVS ) decided to buy The Medicines Company ( MDCO ) at $6.8 million. The Medicines Company’s shareholders will be getting $85 per share in cash  - a 45% premium to its...

Read More

November 25, 2019

0

The FDA Approved AMAG Pharmaceuticals' Product Vyleesi™ for Premenopausal Women with Acquired Generalized Hypoactive Sexual Desire Disorder

AMAG Pharmaceuticals' Vyleesi™ was Approved The U.S. Food and Drug Administration (FDA) approved AMAG Pharmaceuticals’ ( AMAG )  product Vyleesi (bremelanotide injection); a melanocortin receptor agonist for premenopausal women having acquired, generalized hypoactive sexual desire disorder (HSDD)   To be...

Read More

June 24, 2019

0

ImmunoGen: Experiencing Big Internal Changes

ImmunoGen's Big Internal Changes ImmunoGen ( IMGN )   announced a radical impacting decision following the completion of an in-depth operational review aimed at extending the Company’s cash runway; delivering on its promises to continue developing a promising antibody drug...

Read More

June 28, 2019

0

Sarepta announced successful results from a preliminary trial for Duchenne Muscular Dystrophy

Sarepta Therapeutics (SRPT) has news from preliminary Duchenne muscular dystrophy trials. Although the number of recruited patients was only three, the strong positive data excited the media and Wall Street investors who rushed to buy the stock, making it add over...

Read More

June 19, 2018

0

Gilead to File NDA for Rheumatoid Arthritis Drug Filgotinib. Karyopharm Stock Gained 36% in Today's Trading

Gilead to File NDA for Filgotinib for Rheumatoid Arthritis Meeting with the U.S. Food and Drug Administration (FDA)   Gilead ( GILD )   announced it discussed with the agency the Phase 3 FINCH studies;  as well as the ongoing...

Read More

July 3, 2019

0

Gilead's CAR T Product Yescarta Demonstrates Positive Survival Results

Gilead's CAR-T Product Yescarta Results Kite , a  Gilead ( GILD ) subsidiary, announced new data from the ZUMA-1 trial of the CAR T Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. The data from the pivotal...

Read More

December 8, 2019

0

Regeneron's Product Libtayo is Unique and Expected to Become a Best-Seller

The EC Granted Conditional Approval for Regeneron and Sanofi Product Libtayo for CSCC The European Commission ( EC ) conditional approval for Regeneron Pharmaceuticals’  ( REGN ) and   Sanofi’s  ( SNY )   product  Libtayo ® (cemiplimab)  is a historical...

Read More

July 9, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 69
  • 70
  • 71
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy